Clinical trials: Blood Disorder
Hypertension
Pediatric Blood Pressure Clinical Decision Support Tool (PedsBP CDS)
The goal of the PedsBP CDS research project is to adapt a previously tested web-based clinical decision support tool that appropriately identifies high blood pressure in youth for use in a primarily rural health system and…
- Trial name
- NCT05126082
- Testing
- PedsBP CDS
- Where
- United States
- Volunteers
- 41,054 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
HIV/AIDS
Improving Uptake and Adherence to HIV Prevention Services With Pre-exposure Prophylaxis (PrEP), HIV Self- Testing and Adherence Support for Very High Risk HIV-negative Young Women Aged 15-24 in Kampala, Uganda
The main aim is to develop and assess an intervention to enhance initiation and adherence to PrEP among HIV negative young women of high risk (YWHR).
- Trial name
- POPPi (NCT04030520)
- Testing
- POPPi, Comparison
- Where
- Uganda
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Hypogonadism, Male
Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men
This is an open-label, multi-center, single arm study evaluating the blood pressure (BP) changes from baseline (Visit 3) to post-treatment (Visit 5) assessed by ambulatory blood pressure monitoring (ABPM) in LPCN 1021 treated…
- Trial name
- NCT03868059
- Testing
- LPCN 1021
- Where
- 16 sites in United States
- Volunteers
- 138 people
- Sponsor
- Lipocine Inc.
Solid Tumor, Solid Carcinoma
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood.
- Conditions
- Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Hematologic Malignancy
- Trial name
- NCT04552288
- Testing
- Benralizumab
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatitis C, Chronic
A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment
The purpose of this study is to determine the safety, efficacy and tolerability of using two regimens of telaprevir (with and without delayed start) with standard treatment compared to standard treatment alone in participants…
- Trial name
- NCT00703118
- Testing
- Telaprevir, Peg-IFN-alfa-2a, Ribavirin
- Where
- 91 sites in United States, Australia and 14 more
- Volunteers
- 663 people
- Sponsor
- Tibotec BVBA
Hemochromatosis, Cerebrovascular Accident
Stroke With Transfusions Changing to Hydroxyurea
The purpose of this study is to compare standard therapy (transfusions and chelation) with alternative therapy (hydroxyurea and phlebotomy) for the prevention of secondary stroke and management of iron overload in children with…
- Conditions
- Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases
- Trial name
- NCT00122980
- Testing
- Red Cell Transfusions, Iron Chelation, Hydroxyurea
- Where
- 28 sites in United States
- Volunteers
- 134 people
- Sponsor
- St. Jude Children's Research Hospital
Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura
This is an extension study designed to assess the safety and durability of platelet count increases with romiplostim treatment of thrombocytopenic patients with immune (Idiopathic) thrombocytopenia purpura.
- Trial name
- NCT01071954
- Testing
- Romiplostim
- Where
- 31 sites in United States, Australia and 2 more
- Volunteers
- 66 people
- Sponsor
- Amgen
Myelodysplastic Syndromes
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
This was a randomized, double-blind trial to evaluate deferasirox vs placebo in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload .The trial was conducted in 17 countries, started in 2010…
- Trial name
- TELESTO (NCT00940602)
- Testing
- Deferasirox
- Where
- 71 sites in United States, Australia and 14 more
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma
This experimental study evaluates the effects of a series of intensive drug regimens as initial treatment for Multiple Myeloma followed by 2 bone marrow transplantations 4-6 months apart in support of high-dose Melphalan…
- Trial name
- NCT00580372
- Testing
- VAD, High-Dose cyclophosphamide, Hemopoietic stem cell procurement
- Where
- United States
- Volunteers
- 231 people
- Sponsor
- University of Arkansas
COVID-19
VA CoronavirUs Research and Efficacy Studies-1
The purpose of this study is to determine if treatment with convalescent plasma improves the clinical outcomes of Veterans who are hospitalized and require supplemental oxygen due to COVID-19.
- Trial name
- VACURES-1 (NCT04539275)
- Testing
- Convalescent Plasma
- Where
- 24 sites in United States, Puerto Rico
- Volunteers
- 75 people
- Sponsor
- VA Office of Research and Development
Acute Myeloid Leukemia
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
This trial seeked to extend the preliminary findings of efficacy by evaluating MBG453 in combination with hypomethylating agents (HMA) and also Bcl-2 inhibitor venetoclax.
- Trial name
- STIMULUS-AML1 (NCT04150029)
- Testing
- MBG453, Venetoclax, Azacitidine
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 90 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension, Sickle Cell Disease
Macitentan in Pulmonary Hypertension of Sickle Cell Disease
This is a pilot study to assess the safety and efficacy of macitentan in patients with pulmonary hypertension of sickle cell disease. This study will enroll approximately 10 subjects.
- Trial name
- MENSCH (NCT02651272)
- Testing
- macitentan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Boston University
Myelodysplastic Syndrome (MDS)
Darbepoetin Alfa MDS Companion Protocol
The primary objective of the study was to provide required access of investigational product (darbepoetin alfa) beyond the end of the active treatment period (EOATP) of the darbepoetin alfa MDS 20090160 (NCT01362140) study for…
- Trial name
- NCT02175277
- Testing
- Darbepoetin Alfa
- Where
- 4 sites in Belgium
- Volunteers
- 9 people
- Sponsor
- Amgen
Multiple Myeloma
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
The primary aim of this trial is to determine the effect of a short course (i.e., 3 cycles) of low-dose Bortezomib (Velcade) on bone remodeling and on disease progression.
- Trial name
- NCT01062230
- Testing
- Bortezomib (Velcade)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Arkansas
Sickle Cell Disease
Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease
This is a randomized, double-blind, placebo-controlled study in sickle cell disease participants with a history of Vaso-occlusive Crises (VOCs).
- Trial name
- NCT05098028
- Testing
- Low Dose Rifaximin ER, Low Dose Rifaximin DER, High Dose Rifaximin ER
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 44 people
- Sponsor
- Bausch Health Americas, Inc.
Lymphoma, Multiple Myeloma
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).
- Trial name
- ELOQUENT - 2 (NCT01239797)
- Testing
- Lenalidomide, Dexamethasone, Dexamethasone (Oral)
- Where
- 216 sites in United States, Australia and 21 more
- Volunteers
- 646 people
- Sponsor
- Bristol-Myers Squibb
Hypertension
MK-0954E Study in Participants With Hypertension (MK-0954E-357)
This study is being done to evaluate the efficacy, safety, and tolerability of losartan potassium 50 mg (L50) + hydrochlorothiazide 12.5 mg (H12.5) + amlodipine besylate 5 mg (A5) (MK-0954E).
- Trial name
- NCT01302691
- Testing
- losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E), Losartan potassium, Amlodipine besylate
- Volunteers
- 327 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma
This study is being conducted to learn about the effects of SC-PEG, which is a new form of a chemotherapy drug called asparaginase. Asparaginase is used to treat ALL and lymphoblastic lymphoma.
- Trial name
- NCT01574274
- Testing
- SC-PEG, Oncaspar
- Where
- 8 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Myeloid Leukemia
Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
This pilot clinical trial studies the side effects of cytarabine and daunorubicin hydrochloride and to see how well they work in treating patients with newly diagnosed acute myeloid leukemia.
- Trial name
- NCT02971397
- Testing
- Bone Marrow Aspiration and Biopsy, Cytarabine, Daunorubicin Hydrochloride
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat, lenalidomide, and dexamethasone, and to establish the recommended Phase 2 dose for combination treatment to…
- Trial name
- NCT07150091
- Testing
- Belantamab mafodotin, Nirogacestat, Lenalidomide
- Where
- 12 sites in United States, Brazil and 6 more
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.